Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | HCK | P08631 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000899 | 0.80 | BRAF (0.59) | BRAFRAF1YES1CYP2C9 | |
| SCHEMBL1698866 | 0.79 | BRAF (0.52) | BRAFRAF1YES1LCKINSR | |
| Hydrochloric Acid SCHEMBL1697917 | 0.78 | BRAF (0.52) | BRAFRAF1YES1LCKINSR | |
| SCHEMBL5004904 | 0.78 | BRAF (0.76) | BRAFRAF1YES1CYP2C9 | |
| SCHEMBL4931487 | 0.77 | BRAF (0.59) | BRAFRAF1YES1LCKSRC | |
| SCHEMBL3935638 | 0.77 | BRAF (0.59) | BRAFLCKCYP2C9MAPK14 | |
| SCHEMBL1698046 | 0.76 | BRAF (0.49) | BRAFRAF1YES1LCKINSR | |
| SCHEMBL5005096 | 0.76 | BRAF (0.52) | BRAFRAF1YES1SRC | |
| SCHEMBL1698160 | 0.75 | BRAF (0.52) | BRAFRAF1YES1LCKLYN | |
| SCHEMBL1697963 | 0.74 | BRAF (0.53) | BRAFRAF1YES1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | BRAF 1/4885RAF1 4/4885YES1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.